Erenumab Prefilled Syringe
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Facial Pain
Conditions
Facial Pain, Rhinosinusitis
Trial Timeline
Feb 10, 2021 → Jul 11, 2023
NCT ID
NCT04249427About Erenumab Prefilled Syringe
Erenumab Prefilled Syringe is a approved stage product being developed by Amgen for Facial Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT04249427. Target conditions include Facial Pain, Rhinosinusitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04249427 | Approved | Completed |
Competing Products
13 competing products in Facial Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 85 |
| OnabotulinumtoxinA + KYBELLA | AbbVie | Approved | 85 |
| BOTOX®/VISTABEL® | AbbVie | Approved | 85 |
| Rapamune | Pfizer | Phase 1 | 32 |
| EMLA Cream | Sanofi | Phase 3 | 76 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 38 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 30 |
| Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) | Baxter | Phase 2 | 49 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 47 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |